Bispecific antibody targeting of lipid nanoparticles
Angelo Amabile(Icahn School of Medicine at Mount Sinai), Brian D. Brown(Icahn School of Medicine at Mount Sinai), Zhe Yu(Nanoparticle BioChem (United States)), Gürkan Mollaoglu(Icahn School of Medicine at Mount Sinai), Chiara Falcomatà(Icahn School of Medicine at Mount Sinai), Abraham J. P. Teunissen(DMS Imaging (France)), Judit Morlà‐Folch(DMS Imaging (France)), Pedro Silva(Universidade do Porto), Moah Sohn(Precision for Medicine (United States)), Adam Marks(Icahn School of Medicine at Mount Sinai), Yizhou Dong(Icahn School of Medicine at Mount Sinai), Joshua Brody(New York University)
Cited by 10
Related Papers
Immunology of COVID-19: Current State of the Science
|Immunity|2020|1.8k
Expansion and Activation of CD103+ Dendritic Cell Progenitors at the Tumor Site Enhances Tumor Responses to Therapeutic PD-L1 and BRAF Inhibition
|Immunity|2016|1.2k
MYC Drives Progression of Small Cell Lung Cancer to a Variant Neuroendocrine Subtype with Vulnerability to Aurora Kinase Inhibition
|Cancer Cell|2017|607
Role of c-MYC in alternative activation of human macrophages and tumor-associated macrophage biology
|Blood|2011|382
The neutrotime transcriptional signature defines a single continuum of neutrophils across biological compartments
|Nature Communications|2021|335